|
 |
FosrenolThis page contains recent news articles, when available, and an overview of Fosrenol but does not offer medical advice. You should contact your physician with regard to any health issues or concerns...."We are pleased with the performance of ELAPRASE, FOSRENOL, LIALDA, REPLAGAL and VYVANSE and are looking forward to the continued growth of VYVANSE in the MarketWatch BioTrends Releases Quarterly TreatmentTrends(TM): Nephrology ... - Jul 26, 2008 Despite sevelamer's increased share, for the first time, overall satisfaction among the various phosphate binders is highest for Shire's Fosrenol. FOXBusiness Dynepo dropped as Shire places its faith in Vyvanse for growth - Aug 1, 2008 Elaprase (idursulfase) for Hunter syndrome reached $80.8 million, up 89%, while turnover from Fosrenol (lanthanum carbonate) for high blood phosphate levels Pharma Times (subscription), New Study by BioTrends Highlights Practice Management Shifts Among ... - Jun 6, 2008 In the phosphate binder market, Shire expanded share of Fosrenol in all five EU markets. 90% of Nephrologists have now tried Fosrenol and use of the product PharmaLive.com (press release), ADRs in Focus: Shire slips to 52-week low - Jun 10, 2008 On May 1, Shire launched On Track program to help increase the use of its kidney disease drug Fosrenol. But last week, Oppenheimer analyst Brian Abrahams Forbes, FDA Sends Letter to Shire Over Fosrenol Promotional Materials - May 8, 2008 Fosrenol is associated with numerous risks. For example, the PI contains precautions regarding use in patients with acute peptic ulcer, ulcerative colitis, PharmaLive.com (press release), FDA to Shire:Halt Fosrenol materials - May 12, 2008 ...“The pieces misbrand Fosrenol…as they fail to include, among other things, the drug's product indication as well as material contextual information and Medical Marketing and Media, Genzyme’s Renvela well known, still looking to carve its niche - May 23, 2008 ...representatives seemed to have ramped up their product promotion, especially compared to their competitors—Fresenius’ PhosLo and Shire’s Fosrenol. Renal Business Today, Shire Reminder Promo a No No - May 20, 2008 ...of Drug Marketing, Advertising, and Communications last week for improper promotional material associated with the renal disease treatment Fosrenol. PharmExec.com, FDA to Shire: It’s Not Reminder Labeling - May 19, 2008 Some marketing materials intended as reminder labeling for Shire’s phosphate binder Fosrenol misbrand the product because the FDA does not consider them FDA news (subscription), ESA use decreases in pre-dialysis patients, study says - May 7, 2008 However, the survey predicts that Fosrenol is expected to be used significantly more in the future. In CKD care, the report said calcium-based binders are Renal Business Today, BioTrends Releases Two Publications - TreatmentTrends(TM ... - May 6, 2008 Renagel maintains its position as market share leader in dialysis and Fosrenol's share is expected to significantly increase in this population. Biloxi Sun Herald, ALSO NOTED: Apotex assails Canadian goodwill drug program; Amgen ... - May 9, 2008 Report > FDA chided Shire for distributing Fosrenol promotional materials that fail to include information on the drug's indication and risks. FiercePharma, Kidney patients get vascular help - Apr 22, 2008 As a result of this and similar studies, the Food and Drug Administration has now approved the use of PhosLo, Renagel and Fosrenol for the treatment of high Belleville News Democrat, Phosphate-reducing drugs could curb heart disease in kidney patients - Apr 18, 2008 ...the FDA extended the label of phosphate binding drugs, which include calcium acetate (PhosLo), sevelamer (Renagel) and lanthanum carbonate (Fosrenol), CBC.ca, Shire Strives to Increase Adherence Among Chronic Kidney Disease ... - Apr 3, 2008 In addition to offering the highly effective phosphate binder, FOSRENOL (lanthanum carbonate), Shire has created On Track, a program designed to provide Earthtimes, Shire plc: IFRS Results for the Year Ending December 31, 2007 - Mar 25, 2008 FOSRENOL - Hyperphosphatemia FOSRENOL is now available in 25 countries and global sales totalled US$102.2 million for the year to December 31, MSN Money Readily available treatment could help prevent heart disease in ... - Apr 17, 2008 As a result, calcium acetate (PhosLo), sevelamer (Renagel) and lanthanum carbonate (Fosrenol) will be labeled to indicate they are approved for treatment of News from Washington University in St. Louis, Rally to focus on issue of pay equity - Apr 4, 2008 In addition to offering the highly effective phosphate binder, Fosrenol, Shire has created On Track, a program designed to provide resources to patients, Chester DailyLocal.com, Shire: Excellent Performance Across All Areas of the Business and ... - Feb 21, 2008 ...launches - VYVANSE, LIALDA / MEZAVANT and DYNEPO - which have gone well and also continued the roll-out of ELAPRASE and FOSRENOL into new geographies. PharmaLive.com (press release), Shire plc: Excellent Performance Across All Areas of the Business ... - Feb 21, 2008 FOSRENOL(R) - Hyperphosphatemia - International launches continued and FOSRENOL is now available in 24 countries with worldwide sales in 2007 of $102.2 PR Newswire (press release), Vyvanse confounds analysts as net income soars at Shire - Feb 22, 2008 Fourth-quarter sales of Elaprase (idursulfase) for Hunter syndrome reached $57.4 million, up 197%, while turnover from Fosrenol (lanthanum carbonate) for Pharma Times (subscription), Shire Engages Palio - Jan 22, 2008 And, we look forward to becoming a true marketing partner with Shire's FOSRENOL team," said Mike Myers, president of Palio. Shire is a global specialty CNNMoney.com Non-Calcium Phosphate Binder For The Management Of ... - Jan 21, 2008 FOSRENOL is the first of the company's medicines developed in-house from research molecule to market. FOSRENOL is an effective monotherapy treatment for the Medical News Today (press release), MicroMass Wins Three Awards in Global Ad Awards Competition - Jan 9, 2008 Two of the awards honor education materials developed for Shire in support of Fosrenol (lanthanum carbonate), a phosphorous-lowering medication for people PharmaLive.com (press release), Around Tech Valley - Feb 5, 2008 ...was hired by Shire Pharmaceuticals as agency of record to lead professional advertising and promotion for Fosrenol, part of Shire's renal business unit. Albany Times Union, BioTrends Releases Fourth Annual Nephrology TreatmentTrends ... - Jan 28, 2008 ...the shift to non-calcium agents (such as Genzyme's Renagel and Shire's Fosrenol) continues, with Renagel maintaining its position as market leader. Earthtimes, Shire Announces Results of FOSRENOL(R) Study in Pre-Dialysis CKD ... - Nov 6, 2007 ...(1) FOSRENOL is a non-calcium phosphate binder, indicated to treat hyperphosphatemia in end stage renal disease (ESRD), also known as CKD Stage 5. CNNMoney.com Shire's Fosrenol does not meet main goal of trial - Nov 6, 2007 L: Quote, Profile , Research) said on Tuesday its kidney drug Fosrenol had not met the main goal of an intermediate clinical trial aimed at reducing serum Reuters.uk, Shire Announces Results of FOSRENOL(R) Study in Pre-Dialysis CKD ... - Nov 6, 2007 ...(1) FOSRENOL is a non-calcium phosphatebinder, indicated to treat hyperphosphatemia in end stage renaldisease (ESRD), also known as CKD Stage 5. Juraforum.de, Shire Provides Results of Fosrenol Study - Nov 7, 2007 In a Phase II study, Shire’s Fosrenol, a noncalcium phosphate binder indicated to treat hyperphosphatemia in end stage renal disease, reduced serum FDA news (subscription), Shire Says FOSRENOL Fails To Meet Primary Endpoint In Phase II ... - Nov 6, 2007 TO) on Tuesday revealed results of Phase II study of FOSRENOL in chronic kidney disease or CKD patients. According to the company, the clinical data RTT News, FDA advisory committee votes in favor of earlier use of phosphate ... - Nov 7, 2007 Currently, FOSRENOL is indicated to reduce serum phosphate in patients with end stage renal disease (ESRD). The Committee did not reach consensus on which NephrOnline, Shire has its 'best result in history' - Nov 1, 2007 Shire said it was seeing strong growth from a string of its newer products, including Fosrenol for kidney dialysis patients, and Elaprase for the rare Telegraph.co.uk, Help for Dialysis Patients - Oct 30, 2007 ...skeletal deformities and broken bones, and raise a person's risk of heart disease, according to Shire Pharmaceuticals, maker of the new drug, Fosrenol. PakTribune.com, Further Upgrade to 2007 Financial Guidance Based on Strong Revenue ... - Nov 1, 2007 FOSRENOL has now been launched in 23 countries and global sales totaled $28.7 million for the quarter ended September 30, 2007 (2006: $12.2 million). Earthtimes, Shire goes from strength to strength with its ADHD drugs - Nov 2, 2007 Sales of Elaprase (idursulfase) for Hunter syndrome, launched in August2006, reached $55.1 million, while turnover from Fosrenol (lanthanumcarbonate) for Pharma Times (subscription), Shire goes from strength to strength with its ADHD drugs - Nov 2, 2007 Sales of Elaprase (idursulfase) for Hunter syndrome, launched in August 2006, reached $55.1 million, while turnover from Fosrenol (lanthanum carbonate) for Pharma Times (subscription), Billy Joel's wife pens cookbook for patients - Oct 31, 2007 Visit the Web site fosrenol.com (click on "Patients and Caregivers," then "Exclusive Offers,") or call 866-896-6152. The Birmingham News - al.com, London shares close higher, Scottish & Newcastle - Oct 18, 2007 Shire added 32 to end the day at 1203, after the FDA advisory panel opened the door for expanded use of the company's hyperphosphatemia Fosrenol product. FinanzNachrichten.de, Genzyme, Shire, Fresenius seek to broaden drug use - Oct 12, 2007 Shire, a British drug company, makes Fosrenol, while Fresenius of Germany makes PhosLo. Genzyme makes the kidney disease drug Renagel. Reuters.uk, Cooking comfort for chronic patients - Sep 25, 2007 Volume II" is available for free to patients and caregivers and health care professionals by visiting the Web site fosrenol.com, or call 866-896-6152. The Express Times, Katie Lee Joel to Conduct Cooking Demonstration for Local Patients ... - Aug 31, 2007 FOSRENOL.com or by calling (866) 896-6152. Kidney disease is an issue close to Katie's heart because her grandfather was a dialysis patient for several PR Newswire (press release), Shire plc: 2007 Guidance Upgraded as Revenue Growth Accelerates - Jul 26, 2007 CNNMoney.comELAPRASE also made a significant contribution to overall growth as did our other new products FOSRENOL and LIALDA. For the half year, total revenues grew by Shire Slips To Q2 Loss On Write-off Of Assets; Non-GAAP Net Income ... - Jul 26, 2007 RTT News,Fosrenol, which is prescribed to reduce serum phosphate in patients with endstage kidney disease, Replagal, a long-term enzyme replacement therapy for Shire Demonstrates Commitment to Improving Patient Adherence in ... - Jun 24, 2007 Earthtimes.orgFOSRENOL is a newly introduced treatment option in Europe for the nephrologist to use in the management of hyperphosphataemia in CKD patients on dialysis. New hope for kidney dialysis patients - May 9, 2007 Manchester Evening News,Now the introduction of new drug, Fosrenol, means their pill burden can be cut by more than 75 per cent. Rachael Clegg reports. Retired GP Simon Jenkins, Shire storms ahead with strong sales across the board - Apr 26, 2007 Pharma Times (subscription),Sales of Elaprase (idursulfase) for Hunter syndrome, launched in August 2006, reached $26.6 million, while turnover from Fosrenol (lanthanum carbonate) for Shire and GSK upbeat over new drugs after patent losses - Apr 25, 2007 Telegraph.co.uk,Shire, Britain's third-biggest drugs maker, has just launched its drug for Hunter Syndrome, Elaprase, and is in the process of rolling out Fosrenol and ROUNDUP Strong Q1 from Shire lifts hopes for full year; shares advance - Apr 25, 2007 Forbes,Shire still has a busy launch schedule ahead of it, with the roll out of Elaprase, anaemia treatment Dynepo and kidney disease drug Fosrenol across Europe Shire storms ahead with strong sales across the board - 26 Apr 2007 Pharma Times (subscription),Sales of Elaprase (idursulfase) for Hunter syndrome, launched in August 2006, reached $26.6 million, while turnover from Fosrenol (lanthanum carbonate) for Shire and GSK upbeat over new drugs after patent losses - 26 Apr 2007 Telegraph.co.uk,Shire, Britain's third-biggest drugs maker, has just launched its drug for Hunter Syndrome, Elaprase, and is in the process of rolling out Fosrenol and SHIRE PLC - 1st Quarter Results - Apr 25, 2007 PR-Inside.com (Pressemitteilung),In the renal area, the launch of FOSRENOL in Europe continues, and we have gained significant market shares in many countries. DYNEPO was recently launched Strong start to year for Shire - Apr 25, 2007 ShareCast,Attention deficit hyperactivity disorder (ADHD) drug Adderal XR saw sales rise 21% to $249.1m, while sales of hyperphosphatemia treatment Fosrenol almost Shire launches Fosrenol - Apr 2, 2007 Healthcare RepublicShire has launched Fosrenol (lanthanum) for the treatment of hyperphosphataemia in chronic renal failure patients on haemodialysis, or continuous ambulatory Shire Pharmaceuticals Extends 'Kidney-friendly' Cooking Program - Apr 10, 2007 PharmaLive.com (press release),FOSRENOL(R) is available in a broad range of dosage strengths, including the reformulated strengths of 500 mg, 750 mg and 1 g. With the reformulated doses, Shire Pharmaceuticals Extends 'Kidney-Friendly' Cooking Program - Apr 10, 2007 PR Newswire (press release),FOSRENOL(R) is indicated to reduce serum phosphate in patients with end stage renal disease (ESRD). FOSRENOL(R) is not indicated for the treatment of Shire Pharmaceuticals Extends 'Kidney-Friendly' Cooking Program - Apr 10, 2007 PR Newswire (press release),FOSRENOL.com, or by calling 866-896-6152. About Hyperphosphatemia It is important for people with CKD Stage 5 to follow a low phosphorus diet, because most ROUNDUP Strong Q1 from Shire lifts hopes for full year; shares advance - Apr 25, 2007 Forbes,Shire still has a busy launch schedule ahead of it, with the roll out of Elaprase, anaemia treatment Dynepo and kidney disease drug Fosrenol across Europe American Kidney Fund launches Part D grant program - Apr 3, 2007 Renal Business Today,The program covers bone disease medications, including Fosrenol, Hecterol, Phoslo, Renagel, Sensipar and Zemplar. Burton added that the AKF hopes to add American Kidney Fund Launches Medicare Part D Grant Program for ... - Apr 3, 2007 PR Web (press release),This program covers common bone disease medications, including Fosrenol®, Hectorol®, Phoslo®, Renagel®, Sensipar® and Zemplar®. : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |